Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro

Iota-carrageenan study #5 of 10 All Outcomes

2/17 In Vitro

Morokutti-Kurz et al., PLoS ONE, doi:10.1371/journal.pone.0237480 (Peer Reviewed) (In Vitro)
Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro

Source PDF Share Tweet

In Vitro study showing that SARS-CoV-2 is inhibited by iota-carrageenan in a dose dependent manner and to the same extent as other respiratory viruses for which a clinical benefit has been proven. Authors note that clinical data and post market surveillance data show that iota-carrageenan is well-tolerated with very low reported adverse events.

Morokutti-Kurz et al., 2/17/2021, peer-reviewed, 8 authors.

All 10 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit